اخبار و اعلانات

 آمار

تعداد نشریات282
تعداد نشریات سازمان80
تعداد شماره‌ها3,188
تعداد مقالات35,336
تعداد مشاهده مقاله51,465,248
تعداد دریافت فایل اصل مقاله91,333,408
Abdul-Wahab Kadhum, A, Rushdi Abdullah, A, Mujahid Al-Shuwaikh, A. (1402). Increasing Levels of Serum Anti-Spike S1-RBD IgG after 120 Days of the Pfizer-BioNTech-mRNA Second Dose Vaccination. سامانه مدیریت نشریات علمی, 78(3), 1071-1075. doi: 10.22092/ari.2022.359934.2517
A Abdul-Wahab Kadhum; A Rushdi Abdullah; A Mujahid Al-Shuwaikh. "Increasing Levels of Serum Anti-Spike S1-RBD IgG after 120 Days of the Pfizer-BioNTech-mRNA Second Dose Vaccination". سامانه مدیریت نشریات علمی, 78, 3, 1402, 1071-1075. doi: 10.22092/ari.2022.359934.2517
Abdul-Wahab Kadhum, A, Rushdi Abdullah, A, Mujahid Al-Shuwaikh, A. (1402). 'Increasing Levels of Serum Anti-Spike S1-RBD IgG after 120 Days of the Pfizer-BioNTech-mRNA Second Dose Vaccination', سامانه مدیریت نشریات علمی, 78(3), pp. 1071-1075. doi: 10.22092/ari.2022.359934.2517
Abdul-Wahab Kadhum, A, Rushdi Abdullah, A, Mujahid Al-Shuwaikh, A. Increasing Levels of Serum Anti-Spike S1-RBD IgG after 120 Days of the Pfizer-BioNTech-mRNA Second Dose Vaccination. سامانه مدیریت نشریات علمی, 1402; 78(3): 1071-1075. doi: 10.22092/ari.2022.359934.2517

Increasing Levels of Serum Anti-Spike S1-RBD IgG after 120 Days of the Pfizer-BioNTech-mRNA Second Dose Vaccination

Archives of Razi Institute
مقاله 37، دوره 78، شماره 3، مرداد و شهریور 2023، صفحه 1071-1075    اصل مقاله (314.01 K)
نوع مقاله: Original Articles
شناسه دیجیتال (DOI): 10.22092/ari.2022.359934.2517
نویسندگان
A Abdul-Wahab Kadhum* 1؛ A Rushdi Abdullah1؛ A Mujahid Al-Shuwaikh2
1Medical Microbiology Department, Medical College, AL-Iraqia University, Baghdad, Iraq
2Medical Microbiology Department, Medical College, AL-Nahrain University, Baghdad, Iraq
چکیده
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines, such as Pfizer-BioNTech, have demonstrated high efficacy; however, there is limited data on the duration of immune responses besides their relationships with age, gender, body mass index (BMI), and the presence of previous coronavirus disease-2019 (COVID-19) infection. This study aimed to evaluate SARS-COVID-19 Anti-Spike IgG levels after 30 days (one month) and 120 days (four months) of the 2nd dose of Pfizer-BioNTech vaccine given to medical students at Al-Iraqi University, Baghdad, Iraq. This study was performed after the obtainment of the acceptance and approval of the Medical College of Al-Iraqi University and the Iraqi Ministry of Health. Two groups of students were randomly picked up from the Medical College of Al-Iraqi University. They were completely vaccinated by administering two doses of Pfizer-BioNTech/0.5 ml for each dose. After taking their permission,  5 ml of their blood (one group after one month and the second group after four months of vaccination) was drawn in the Higher Education lab inside the Medical College of Al-Iraqi University. It took approximately four months to collect the samples (from October 2021 until February 2022). Following that, serological analysis was done for measuring the SARS-CoV-2 spike protein IgG by using Elabscience/SARS-CoV-2 spike protein IgG ELISA Kit (USA) (+ve <0.06) that was performed in the Higher Education lab of Medical College of Al-Iraqi University. Demographic data were also collected from participants, including age, gender, BMI, blood group, and the presence of previous COVID-19 infection. For statistical analysis, SPSS (version 26) and STATISTICA (version 12) were used to input, check, and analyze data. Standard approaches of frequencies and percentages were used for qualitative variables, while for quantitative variables, mean±standard deviation was used. A P-value of <0.05 was considered a significant plasma level of the SARS-COVID-19 Anti-Spike IgG. The study results showed that in group 1 (after one month of the 2nd dose), the male-female ratio was 62.2: 37.8, the mean age of the vaccinated students was 28.2000 years old, and the BMI was 25.5454 kg/m2 with 33.3% previously COVID-19 infected individuals. In group 2 (after four months of the 2nd dose), the male-female ratio was 44.4: 55.6, the mean age of the vaccinated students was 25.8444 years old, and the BMI was 24.7584 kg/m2 with 24.4% previously COVID-19 infected individuals. The plasma levels of SARS-COVID-19 Anti-Spike IgG after the 2nd dose of the Pfizer-BioNTech vaccine in group 1 (one month) and group 2 (four months) were statistically non-parametric. Once the independent two samples Mann-Whitney test was used, a significant difference (P<0.05) was observed in SARS-COVID-19 Anti-Spike IgG plasma levels after 30 days of the 2nd dose of the Pfizer-BioNTech vaccine administration, compared to the 120 days of administration. In conclusion, SARS-COVID-19 Anti-Spike IgG levels significantly increased in group 2 (four months after the 2nd dose of the Pfizer-BioNTech vaccine), compared to group 1 (one month after the 2nd dose of the Pfizer-BioNTech vaccine).
کلیدواژه‌ها
SARS-COVID-19 Anti-Spike IgG؛ Pfizer-BioNTech vaccine؛ Medical students؛ Al-Iraqi University
سایر فایل های مرتبط با مقاله
مراجع
  1. Shoenfeld Y. Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning. Autoimmun Rev. 2020;19(6):102538.
  2. Musa SS, Tariq A, Yuan L, Haozhen W, He D. Infection fatality rate and infection attack rate of COVID-19 in South American countries. Infect Dis Poverty. 2022;11(1):40.
  3. Tao J, Zhang X, Musa SS, Yang L, He D. High Infection Fatality Rate Among Elderly and Risk Factors Associated With Infection Fatality Rate and Asymptomatic Infections of COVID-19 Cases in Hong Kong. Front Med. 2021;8:678347
  4. Mascellino MT, Di Timoteo F, De Angelis M, Oliva A. Overview of the main anti-SARS-CoV-2 vaccines: mechanism of action, efficacy and safety. Infect Drug Resist. 2021:3459-76.
  5. Liu B, Li M, Zhou Z, Guan X, Xiang Y. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information. 2020.
  6. Nagy A, Alhatlani B. An overview of current COVID-19 vaccine platforms. Comput Struct Biotechnol J. 2021;19:2508-17.
  7. Al-Metwali BZ, Al-Jumaili AA, Al-Alag ZA, Sorofman B. Exploring the acceptance of COVID-19 vaccine among healthcare workers and general population using health belief model. J Eval Clin Pract. 2021;27(5):1112-22.
  8. Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2021;21(2):83-100.
  9. Chauhan G, Madou MJ, Kalra S, Chopra V, Ghosh D, Martinez-Chapa SO. Nanotechnology for COVID-19: Therapeutics and Vaccine Research. ACS Nano. 2020;14(7):7760-82.
  10. Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586(7830):594-9.
  11. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature Med. 2021;27(7):1205-11.
  12. Wisnewski AV, Luna JC, Redlich CA. Human IgG and IgA responses to COVID-19 mRNA vaccines. PloS One. 2021;16(6):e0249499.
  13. Dhar Chowdhury S, Oommen AM. Epidemiology of COVID-19. J Dig Endosc. 2020;11(01):03-7.
  14. Ward H, Cooke G, Whitaker M, Redd R, Eales O, Brown JC, et al. REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England. MedRxiv. 2021.
  1. Young J, Thone M, Jik Y. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ' s public news and information. Adv Drug Deliv Rev J. 2020;25.
  2. Saad-Roy CM, Morris SE, Metcalf CJE, Mina MJ, Baker RE, Farrar J, et al. Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes. Science. 2021;372(6540):363-70.
  3. Tretyn A, Szczepanek J, Skorupa M, Jarkiewicz-Tretyn J, Sandomierz D, Dejewska J, et al. Differences in the Concentration of Anti-SARS-CoV-2 IgG Antibodies Post-COVID-19 Recovery or Post-Vaccination. Cells. 2021;10(8):1952.
  4. Ali H, Alahmad B, Al-Shammari AA, Alterki A, Hammad M, Cherian P, et al. Previous COVID-19 Infection and Antibody Levels After Vaccination. Front Public Health. 2021;9.
  5. Bergamaschi C, Terpos E, Rosati M, Angel M, Bear J, Stellas D, et al. Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. Cell Rep. 2021;36(6):109504.
آمار
تعداد مشاهده مقاله: 2,369
تعداد دریافت فایل اصل مقاله: 6,705


counter
سامانه مدیریت نشریات علمی. طراحی و پیاده سازی از سیناوب